Skip to main content
Premium Trial:

Request an Annual Quote

GenePOC Receives CE Mark for Drug-Resistant Bacteria Test

NEW YORK (GenomeWeb) – GenePOC announced today the CE marking of its Carba assay for carbapenemase-producing organisms, a class of bacteria resistant to carbapenem antibiotics.

The PCR-based in vitro diagnostic is designed for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP gene sequences, which are associated with carbapenem resistance. It can provide results for up to eight sample in approximately 70 minutes and runs on the Canadian firm's Revogene automated instrument.

"A test [that] offers rapid and accurate results will contribute to the identification of colonized patients, therefore limit the spread of these organisms in healthcare settings and save on hospital costs," GenePOC CEO Patrice Allibert said in a statement. "Our GenePOC Carba assay also demonstrates the power of our technology to be compatible with panel detection."

Earlier this year, GenePOC received US Food and Drug Administration clearance for its group A Streptococcus test. The Revogene system won FDA clearance in mid-2017.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.